Press coverage about Humana (NYSE:HUM) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Humana earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news stories about the insurance provider an impact score of 46.100154503389 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Humana Releases its 2018 Bold Goal Progress Report: More Healthy Days Achieved, Social Determinants of Health Addressed, and Involvement with Local Communities Expanded (markets.financialcontent.com)
- Humana To Pay $2.5M To Resolve DOL’s Pay Bias Claims (law360.com)
- Former Humana exec Kristine Seymour joins Michael Best Strategies (biztimes.com)
- Two Leading Proxy Advisory Firms Recommend Kindred Stockholders Vote “FOR” the Transaction with TPG Capital, Welsh, Carson, Anderson & Stowe and Humana Inc. (markets.financialcontent.com)
- Humana Settles Pay Bias Claims for $2.5 Million – The National Law Review (natlawreview.com)
Shares of Humana stock traded down $2.23 during trading hours on Thursday, reaching $268.58. The company’s stock had a trading volume of 319,516 shares, compared to its average volume of 1,103,880. The stock has a market capitalization of $37,670.43, a PE ratio of 16.11, a price-to-earnings-growth ratio of 1.48 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85. Humana has a fifty-two week low of $203.48 and a fifty-two week high of $293.35.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.74%. The ex-dividend date is Wednesday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio (DPR) is 9.59%.
Humana announced that its Board of Directors has initiated a stock repurchase plan on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s management believes its shares are undervalued.
A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Cantor Fitzgerald reiterated a “hold” rating and set a $250.00 price target on shares of Humana in a research report on Wednesday, February 7th. Oppenheimer upped their price target on Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Finally, Leerink Swann upped their price objective on shares of Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Eight analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average target price of $270.47.
In other Humana news, insider M Todoroff Christopher sold 16,389 shares of Humana stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total value of $4,480,260.93. Following the sale, the insider now owns 13,447 shares of the company’s stock, valued at approximately $3,676,006.39. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce D. Broussard sold 14,075 shares of Humana stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the completion of the sale, the chief executive officer now directly owns 113,896 shares in the company, valued at approximately $31,243,950.72. The disclosure for this sale can be found here. Insiders have sold a total of 31,660 shares of company stock worth $8,668,218 in the last three months. 0.60% of the stock is owned by corporate insiders.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.